Pliant Therapeutics, Inc.
PLRX
M
|
$31.74
-1.67%
-1.73%
310K
|
Health Technology
(0.0% 1d) (64.0% 1m) (176.0% 1y) (0.0% 2d) (-2.3% 3d) (-4.9% 7d) (Infinity% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 1,547,623,959
http://www.pliantrx.com
Sec Filling | Patents | 62 employees
(US) Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
add to watch list email alert is off
Press-releases
Pliant Therapeutics to Participate in Upcoming Investor Events
Published: 2023-02-07 (Crawled : 14:00) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -2.67%
H: 0.0%
C: 0.0%
therapeutics
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
Published: 2023-02-02 (Crawled : 13:20) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -0.3%
H: 2.42%
C: -1.93%
pln-1010 treatment fda clearance drug for therapeutics tumors
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Published: 2023-01-27 (Crawled : 22:00) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
| Email alert
Add to watchlist
offering therapeutics
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
JNJ | $163.61 0.13% 0.24% 4.7M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 4.99%
H: 0.0%
C: 0.0%
therapeutics
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
Published: 2023-01-25 (Crawled : 03:00) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 4.99%
H: 0.0%
C: 0.0%
offering therapeutics
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
Published: 2023-01-22 (Crawled : 20:20) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 58.7%
H: 4.17%
C: -13.58%
fibrosis trial therapeutics positive phase 2b
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-12-15 (Crawled : 21:00) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -1.72%
H: 3.29%
C: 3.02%
pln-7480 treatment fibrosis designation for therapeutics
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Published: 2022-11-15 (Crawled : 13:00) - globenewswire.com
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 3.37%
H: 5.71%
C: 3.14%
therapeutics
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
Published: 2022-09-15 (Crawled : 14:00) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: -1.4%
H: 0.96%
C: -0.04%
therapeutics
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Published: 2022-09-01 (Crawled : 14:20) - biospace.com/
PLRX M | $31.74 -1.67% -1.73% 310K
|
Health Technology
|
| O: 1.76%
H: 4.84%
C: 3.47%
pln-7480 fibrosis trial therapeutics review positive phase 2b
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 57% | 43% |
Top 10 Gainers
CZOO | $0.2001 -16.63% 1874.01% 3.3M
|
AVRO | $1.69 93.7% 54.08% 38M
|
Health Technology
CELZ | $1.04 101.04% 50.26% 140M
|
WETG | $0.65 58.54% 37.88% 27M
|
GFAI | $0.5408 58.36% 36.88% 89M
|
KPRX | $6.94 52.53% 34.15% 36M
|
Manufacturing
PRFX | $0.7236 44.72% 30.07% 14M
|
Health Technology
BJDX | $0.64 37.16% 23.51% 2.8M
|
SOUN 4 | $4.63 28.61% 22.08% 62M
|
THCH | $5.3 26.19% 19.69% 750K
|
n/a
Last 48 Hours Insiders Buying
PMT P 10340 | $14.42 0.35% -0.07% 730K
|
Finance
|
01:30
APPN P 50000 | $42.79 -1.45% -1.47% 300K
|
Technology Services
|
23:30
BOKF P 1000 | $103.18 -1.45% -1.37% 110K
|
Finance
|
23:00
IVAC P 15000 | $7.08 1.87% 1.7% 920K
|
Electronic Technology
|
22:30
FKYS P 599 | $21.75 0.37% 700
|
Finance and Insurance
|
22:20
ASRV P 1884 | $4.015 0.38% 0.74% 4.2K
|
Finance
|
19:40
RILY P 20000 | $39.6 -10.2% -13.05% 2M
|
Finance
|
19:40
BSGM P 349323 | $1.17 2.63% 2.56% 260K
|
Health Technology
|
17:30
HPKEW 4 | $16.0 0%
|
Industrial Services
|
23:50